Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Canakinumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis`s Biologic Ilaris Receives Suppl Approval in US
    Novartis`s Biologic Ilaris Receives Suppl Approval in US

    01 Nov 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125319

    FDA
    01 Nov 2024
    Share Share
    Novartis’ Canakinumab Flunks Another Phase III NSCLC Trial
    Novartis’ Canakinumab Flunks Another Phase III NSCLC Trial

    16 Aug 2022

    // Tristan Manalac BIOSPACE

    https://www.biospace.com/article/novartis-canakinumab-continues-losing-streak-with-phase-iii-nsclc-flop/

    Tristan Manalac BIOSPACE
    16 Aug 2022
    Share Share
    Novartis looks for silver lining after 2nd Ilaris NSCLC flop
    Novartis looks for silver lining after 2nd Ilaris NSCLC flop

    26 Oct 2021

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/novartis-looks-for-silver-lining-2b-ilaris-canakinumab-repurposing-2nd-lung-cancer-failure

    Angus Liu FIERCEPHARMA
    26 Oct 2021
    Share Share
    Strike two for Novartis’ lung cancer antibody canakinumab
    Strike two for Novartis’ lung cancer antibody canakinumab

    26 Oct 2021

    // PHARMAPHORUM

    https://pharmaphorum.com/news/strike-two-for-novartis-lung-cancer-antibody-canakinumab/

    PHARMAPHORUM
    26 Oct 2021
    Share Share
    Novartis lung cancer drug fails another Phase III trial
    Novartis lung cancer drug fails another Phase III trial

    25 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/25/2319489/0/en/Novartis-top-line-results-for-CANOPY-1-Phase-III-study-support-further-evaluation-of-canakinumab-in-lung-cancer.html

    GLOBENEWSWIRE
    25 Oct 2021
    Share Share
    Novartis hits another setback in plan to repurpose rare disease drug
    Novartis hits another setback in plan to repurpose rare disease drug

    25 Oct 2021

    // Ned Pagliarulo BIOPHARMADIVE

    https://www.biopharmadive.com/news/novartis-canakinumab-lung-cancer-study-results-negative/608820/

    Ned Pagliarulo BIOPHARMADIVE
    25 Oct 2021
    Share Share